Aptose Biosciences Inc. (TSE:APS - Get Free Report) NASDAQ: APTO's share price crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of C$2.46 and traded as low as C$1.16. Aptose Biosciences shares last traded at C$1.18, with a volume of 13,665 shares traded.
Analyst Upgrades and Downgrades
Separately, Alliance Global Partners raised Aptose Biosciences to a "strong-buy" rating in a report on Thursday, February 27th.
View Our Latest Report on APS
Aptose Biosciences Trading Down 4.8%
The company has a market cap of C$50.81 million, a price-to-earnings ratio of -0.24 and a beta of 1.36. The firm has a 50 day moving average price of C$2.46 and a two-hundred day moving average price of C$5.44. The company has a quick ratio of 5.41, a current ratio of 1.05 and a debt-to-equity ratio of -117.37.
Aptose Biosciences Company Profile
(
Get Free Report)
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aptose Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aptose Biosciences wasn't on the list.
While Aptose Biosciences currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
